ANTOLRX | Antigen Tolerance Pharmaceuticals

Revolutionizing the Treatment of Autoimmune Diseases

About Us

Our Vision

Addressing significant unmet needs in the field of autoimmunity through the development of novel patented therapies for treatment of disease.

Join us at the Antigen-Specific Immune Tolerance Drug Development Conference!

Mar 18, 2019

Dr. Sara Tezza will be presenting data on AnTolRx's antigen-specific nanoformulation platform. Join us in Boston March 26-28, 2019. http://as-immunetolerance.com

ANTOLRX ANNOUNCES PFIZER EXERCISES OPTION TO LICENSE IMMUNE TOLERANCE THERAPY FOR POTENTIAL TREATMENT OF TYPE 1 DIABETES

Mar 5, 2019

CAMBRIDGE, Mass., March 5,2019 – AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance, today announced that Pfizer Inc. (NYSE: PFE) has exercised the option granted under a June 2016 agreement to license an immune...